Drug Profile
INCB 057643
Alternative Names: INCB 57643; INCB057643; LIMBER-103Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Incyte Corporation
- Class Antineoplastics; Oxazines; Pyridines; Pyrroles; Small molecules; Sulfones
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Myelofibrosis
- No development reported Myelodysplastic syndromes
- Discontinued Cancer
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Combination therapy, Late-stage disease, Second-line therapy or greater) in Canada (PO)
- 28 Mar 2024 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Combination therapy, Late-stage disease, Second-line therapy or greater) in Finland (PO)
- 28 Mar 2024 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Combination therapy, Late-stage disease, Second-line therapy or greater) in Italy (PO)